Chinese medical journal
-
Chinese medical journal · Aug 2013
Tamoxifen-resistant breast cancer cells possess cancer stem-like cell properties.
Cancer stem cells (CSCs) are the cause of cancer recurrence because they are resistant to conventional therapy and contribute to cancer growth and metastasis. Endocrinotherapy is the most common breast cancer therapy and acquired tamoxifen (TAM) resistance is the main reason for endocrinotherapy failure during such therapy. Although acquired resistance to endocrine treatment has been extensively studied, the underlying mechanisms are unclear. We hypothesized that breast CSCs played an important role in TAM-induced resistance during breast cancer therapy. Therefore, we investigated the biological characteristics of TAM-resistant (TAM-R) breast cancer cells. ⋯ TAM-R MCF7 cells possess CSC characteristics and may be responsible for TAM resistance during breast cancer therapy.
-
Chinese medical journal · Jul 2013
Clinicopathological significance of altered metallothionein 2A expression in gastric cancer according to Lauren's classification.
Dysregulated metallothionein 2A (MT2A) has been implicated in carcinogenesis. The purpose of this study was to investigate the expression of MT2A in gastric cancer (GC) and its correlation with prognosis. ⋯ Expression status of MT2A might be a useful prognostic biomarker for GC, especially when used in combination with Lauren's classification.
-
Chinese medical journal · Jul 2013
Comparative StudyComparative outcomes between cord blood transplantation and bone marrow or peripheral blood stem cell transplantation from unrelated donors in patients with hematologic malignancies: a single-institute analysis.
Umbilical cord blood (UCB) has grown substantially as an alternative source of hematopoietic stem cells for unrelated donor transplantation in both adult and pediatric patients. Our aim was to assess the leukemia-free survival (LFS) and some primary results, such as hematologic recovery, risk of graft-versus-host disease (GVHD), relapse, and long-term survival, after unrelated cord blood transplantation compared with the outcomes of transplantations from other unrelated graft source. ⋯ These data support the use of UCB donors as an alternative allogeneic donor.